Q1 2013

Filed May 20, 2013 · 10-Q · 50 days after period end · 0001193125-13-228070

Q1 2013 · 10-Q

Revenue—

Net Income

-$60.55K

no prior Q1 2012 on file

EPS, diluted—

Operating Income-$90,545—

Operating Cash Flow-$81,230—

Same quarter

no prior Q1 2012 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ended Mar 31, 2013 · filed May 20, 2013 · 50 d after period end

Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR